Clinical Implications of Lipid Genetics for Cardiovascular Disease

Current Cardiovascular Risk Reports

Volumn 4, Issue 6, 2010, Pages 461-468

  Strong, Alanna ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular disease; Genome wide association; HDL; Human genetics; LDL; Lipid; Lipoprotein; Mendelian randomization

Indexed keywords

EID: 84865082949     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0131-7     Document Type: Review

References (56)

1. Lloyd-Jones D, et al.: Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121: 948-954.
2. Hobbs DJ: Disorders of lipoprotein metabolism. In Harrison's Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, et al.: New York: McGraw Hill Publishers; 2007: 2416-2429.
3. Goldstein J, Hobbs H, Brown M: Familial hypercholesterolemia. In The metabolic and Molecular Bases of Inherited Disease. Edited by Scriver C, Beaudet A, Sly W, Valle D. New York: McGraw-Hill; 2001: 2863-2913.
4. Goldstein JL, Brown MS: The LDL receptor. Arterioscler Thromb Vasc Biol 2009, 29: 431-438.
5. Garcia CK, et al.: Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001, 292: 1394-1398.
6. Mishra SK, Watkins SC, Traub LM: The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc Natl Acad Sci U S A 2002, 99: 16099-16104.
7. Arca M, et al.: Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002, 359: 841-847.
8. Abifadel M, et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34: 154-156.
9. Horton JD, et al.: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32: 71-77.
10. Cunningham D, et al.: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007, 14: 413-419.
11. Hansen PS: Familial defective apolipoprotein B-100. Dan Med Bull 1998, 45: 370-382.
12. Ejarque I, et al.: Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Transl Res 2008, 151: 162-167.
13. Myant NB: Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993, 104: 1-18.
14. Bhattacharyya AK, Connor WE: Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974, 53: 1033-1043.
15. Salen G, et al.: Sitosterolemia. J Lipid Res 1992, 33: 945-955.
16. Berge KE, et al: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290: 1771-1775.
17. Oram JF, Vaughan AM: ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006. 99: 1031-1043.
18. Tarugi P, et al.: Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 2007, 195: e19-27.
19. Schonfeld G: Familial hypobetalipoproteinemia: a review. J Lipid Res 2003, 44: 878-883.
20. Sankatsing RR, et al.: Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25: 1979-1984.
21. Sharp D, et al.: Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993, 365: 65-69.
22. Gordon DA, Jamil H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim Biophys Acta 2000, 1486: 72-83.
23. Dische MR, Porro RS: The cardiac lesions in Bassen-Kornzweig syndrome. Report of a case, with autopsy findings. Am J Med 1970, 49: 568-571.
24. Cohen J, et al.: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37: 161-165.
25. Zhao Z, et al.: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79: 514-523.
26. Cohen JC, et al.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354: 1264-1272.
27. Kathiresan S: A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med 2008, 358: 2299-2300.
28. Oram JF, Lawn RM: ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001, 42: 1173-1179.
29. Hobbs HH, Rader DJ: ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999, 104: 1015-1017.
30. Frikke-Schmidt R, et al.: Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299: 2524-2532. This study addressed whether heterozygous individuals for four ABCA1 loss-of-function mutations were at increased risk for ischemic heart disease compared with non-carriers. Their data suggests that although carriers of loss-of-function ABCA1 mutations have a 17-mg/dL lower HDL-C level than non-carriers, they are not at increased risk for ischemic heart disease.
31. Brousseau ME, et al.: Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis 2001, 154: 607-611.
32. Kuivenhoven JA, et al.: The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997, 38: 191-205.
33. Calabresi L, et al.: The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 2005, 25: 1972-1978.
34. Hovingh GK, et al.: Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005, 112: 879-884.
35. Calabresi L, et al.: Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009, 120: 628-635. This study addressed whether low HDL due to heterozygosity for LCAT mutations is associated with increased risk of CVD compared with non-carriers, using IMT as a marker for preclinical atherosclerotic disease. This study found no association between increased IMT and heterozygosity for LCAT mutations, suggesting that low HDL due to LCAT deficiency is not associated with increased atherosclerotic disease.
36. Lambert G, et al.: Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 2001, 276: 15090-15098.
37. Ng DS, et al.: Oxidative stress is markedly elevated in lecithin: cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002, 277: 11715-11720.
38. Furbee JW Jr, et al.: Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 2002, 277: 3511-3519.
39. Rader DJ: Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script. Circulation 2009, 120: 549-552.
40. Ng DS, et al.: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994, 93: 223-229.
41. Franceschini G, et al.: Apolipoprotein AIMilano. Disulfide-linked dimers increase high density lipoprotein stability and hinder particle interconversion in carrier plasma. J Biol Chem 1990, 265: 12224-12231.
42. Dastani Z, et al.: A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians. Atherosclerosis 2006, 185: 127-136.
43. Hovingh GK, et al.: A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004, 44: 1429-1435.
44. Inazu A, et al.: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323: 1234-1238.
45. Barter PJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23: 160-167.
46. Saxena R, et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316: 1331-1336.
47. Kathiresan S, et al.: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40: 189-197. This GWAS identified 18 total loci for lipid traits and six novel loci, including the 1p13 SORT1 locus, as a genome-wide significant determinant of LDL-C.
48. Willer CJ, et al.: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40: 161-169. This GWAS identified 11 total loci for lipid traits and six novel loci, including the 1p13 SORT1 locus. This study also found an association between 11 LDL SNPs and CVD.
49. Kathiresan S, et al.: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41: 56-65. This GWAS identified 30 total loci for lipid traits, with 10 novel loci.
50. Teslovich TM, et al.: Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2009, 466: 707-713. The largest GWAS for lipid traits to date, it identified 95 total loci for lipid traits with 59 novel loci. This study also identified 29 lipid loci also associated with CVD. Many of the significant SNPs were associated with gene expression changes in liver and adipose and were also replicated in three non-European populations. Three novel genes were also overexpressed and/or knocked down in mice and shown to have an effect on lipids.
51. Lanktree MB, et al.: Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res 2009, 50: 1487-1496.
52. Nakayama K, et al.: Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J Med Genet 2009, 46: 370-374.
53. Musunuru K, et al.: From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2009, 466: 714-719. This study shows that an SNP in the 1p13 locus creates a CEBP transcription factor binding site and increases hepatic expression of the SORT1 gene. Through overexpression and knockdown studies in mice, this study shows that sortilin affects plasma LDL-C levels by influencing very low-density lipoprotein secretion.
54. Samani NJ, et al.: Genomewide association analysis of coronary artery disease. N Engl J Med 2007, 357: 443-453. This is a seminal GWAS of CAD and myocardial infarction.
55. Kathiresan S, et al.: Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41: 334-341. This is a seminal GWAS of CAD and myocardial infarction.
56. Edmondson AC, et al.: Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009, 119: 1042-1050. This study identified loss of function mutations in LIPG (endothelial lipase) in individuals with high HDL and showed that these mutations lead to reduced lipolytic activity of endothelial lipase.